CA2864133A1 - Methods related to treatment of inflammatory diseases and disorders - Google Patents

Methods related to treatment of inflammatory diseases and disorders Download PDF

Info

Publication number
CA2864133A1
CA2864133A1 CA2864133A CA2864133A CA2864133A1 CA 2864133 A1 CA2864133 A1 CA 2864133A1 CA 2864133 A CA2864133 A CA 2864133A CA 2864133 A CA2864133 A CA 2864133A CA 2864133 A1 CA2864133 A1 CA 2864133A1
Authority
CA
Canada
Prior art keywords
expression
level
gene
inflammatory agent
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CA2864133A
Other languages
English (en)
French (fr)
Inventor
Klaus Steensgaard FREDERIKSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CA2864133A1 publication Critical patent/CA2864133A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2864133A 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders Withdrawn CA2864133A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12154917.4 2012-02-10
EP12154917 2012-02-10
US201261597924P 2012-02-13 2012-02-13
US61/597,924 2012-02-13
PCT/EP2013/052629 WO2013117751A2 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders

Publications (1)

Publication Number Publication Date
CA2864133A1 true CA2864133A1 (en) 2013-08-15

Family

ID=48948117

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864133A Withdrawn CA2864133A1 (en) 2012-02-10 2013-02-11 Methods related to treatment of inflammatory diseases and disorders

Country Status (8)

Country Link
EP (1) EP2812445A2 (es)
KR (1) KR20140124767A (es)
CN (1) CN104204230A (es)
AU (1) AU2013217940A1 (es)
BR (1) BR112014019274A2 (es)
CA (1) CA2864133A1 (es)
MX (1) MX2014009490A (es)
WO (1) WO2013117751A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240095363A (ko) * 2016-05-20 2024-06-25 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
CN110244053B (zh) * 2019-05-09 2022-03-11 北京大学第三医院（北京大学第三临床医学院） 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4713901A (en) 1999-12-07 2001-06-25 Parthus Technologies Plc Model for charge pump phase-locked loop
EP1616575B1 (en) 1999-12-23 2012-06-06 ZymoGenetics, Inc. Method for treating inflammation
DE10227527A1 (de) 2002-06-20 2004-01-08 Clariant Gmbh Verfahren zur Herstellung von Disazopigmenten
US7435800B2 (en) 2003-05-23 2008-10-14 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
EP2143733A1 (en) 2003-11-21 2010-01-13 ZymoGenetics, Inc. ANTI-IL-20 antibodies and binding partners and methods of using in inflammation
WO2007006858A2 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same
IES20050495A2 (en) 2005-07-20 2006-11-01 Minroc Techn Promotions Ltd A drill bit assembly for fluid-operated percussion drill tools
WO2007038501A2 (en) 2005-09-27 2007-04-05 The Feinstein Institute For Medical Research Rheumatoid arthritis markers
WO2007081465A2 (en) 2005-12-09 2007-07-19 Chi-Mei Medical Center Antibodies to interleukin-20 and method for inhibiting interleukin-20 induced cell proliferation
EP1857559A1 (en) 2006-05-16 2007-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting responsiveness to TNF alpha blocking agents
US20100267575A1 (en) * 2006-10-17 2010-10-21 Childrens Hospital Medical Center Gene array technique for predicting response in inflammatory bowel diseases
WO2008056198A1 (en) 2006-11-09 2008-05-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for predicting therapeutic responsiveness to tnf-alpha blocking agents
US20100273671A1 (en) 2007-03-01 2010-10-28 Universite Catholique De Louvain Method for the determination and the classification of rheumatic conditions
WO2008132176A2 (en) 2007-04-27 2008-11-06 Universite Catholique De Louvain Method for evaluating the response of an individual to tnf blocking therapy
NZ581742A (en) 2007-06-08 2012-09-28 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
RU2011101969A (ru) 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
AU2009285585A1 (en) 2008-08-28 2010-03-04 Wyeth Llc Uses of IL-22, IL-17, and IL-1 family cytokines in autoimmune diseases
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
WO2010113096A1 (en) * 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
EP3211094A3 (en) 2009-09-03 2017-11-01 F. Hoffmann-La Roche AG Methods for treating, diagnosing, and monitoring rheumatoid arthritis
US8580528B2 (en) * 2009-10-16 2013-11-12 Stichting Vu-Vumc Method for prognosticating the clinical response of a patient to B-lymphocyte inhibiting or depleting therapy
EP2576824A2 (en) * 2010-06-07 2013-04-10 Roche Diagnostics GmbH Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment

Also Published As

Publication number Publication date
EP2812445A2 (en) 2014-12-17
KR20140124767A (ko) 2014-10-27
MX2014009490A (es) 2014-08-29
CN104204230A (zh) 2014-12-10
AU2013217940A1 (en) 2014-07-31
WO2013117751A2 (en) 2013-08-15
BR112014019274A2 (pt) 2017-06-27
WO2013117751A3 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
Christmann et al. miR-155 in the progression of lung fibrosis in systemic sclerosis
Fuchs et al. 4sUDRB-seq: measuring genomewide transcriptional elongation rates and initiation frequencies within cells
Meng et al. Identification of latent tuberculosis infection-related microRNAs in human U937 macrophages expressing Mycobacterium tuberculosis Hsp16. 3
EP2559772B1 (en) Methods for determining a hepatocellular carcinoma subtype
Cao et al. Role of MiRNAs in inflammatory bowel disease
JP5727484B2 (ja) Ｉ型インターフェロン診断法
Zheng et al. Differential microRNA expression in human macrophages with Mycobacterium tuberculosis infection of Beijing/W and non-Beijing/W strain types
Cai et al. STAT3-dependent transactivation of miRNA genes following Toxoplasma gondii infection in macrophage
Hussein et al. Association of tumor necrosis factor alpha and its receptor polymorphisms with rheumatoid arthritis in female patients
JP2016507233A5 (es)
Alacam et al. miR-181b-5p, miR-195-5p and miR-301a-3p are related with treatment resistance in schizophrenia
Barzago et al. A novel infection-and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients
Shi et al. MicroRNA-219a-5p suppresses intestinal inflammation through inhibiting Th1/Th17-mediated immune responses in inflammatory bowel disease
JP2011509071A5 (es)
Guo et al. Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application
JP2012533322A5 (es)
Dehghani et al. Evaluation of miR-181b and miR-126-5p expression levels in T2DM patients compared to healthy individuals: relationship with NF-κB gene expression
Wang et al. Emerging insights into the role of epigenetics and gut microbiome in the pathogenesis of Graves’ ophthalmopathy
JP2017532961A (ja) Ｓｍａｄ７アンチセンスオリゴヌクレオチドによる対象を処置するための方法および組成物
Kõks et al. Psoriasis-specific RNA isoforms identified by RNA-seq analysis of 173,446 transcripts
EP3510167B1 (en) Methods and compositions for predicting chronic lung allograft dysfunction
JP2022512796A (ja) Ｉ型インターフェロンシグネチャー及び使用方法
Wu et al. LncRNA NEAT1 promotes gastric cancer progression via miR-1294/AKT1 axis
CA2864133A1 (en) Methods related to treatment of inflammatory diseases and disorders
Mohamed et al. Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis

Legal Events

Date Code Title Description
AZWI Withdrawn application

Effective date: 20141219

AZWI Withdrawn application

Effective date: 20141219